Tanvex Biopharma stock analysis
Tanvex Biopharma (TANVF) Stock Price & Analysis
TANVF Stock Chart & Stats
- Day’s Range
- N/A
- 52-Week Range
- N/A
- Previous Close
- N/A
- Volume
- N/A
- Average Volume (3M)
- N/A
- Market Cap
- $221.18M
- Enterprise Value
- $12.13B
- Total Cash (Recent Filing)
- $592.56M
- Total Debt (Recent Filing)
- $2.08B
- Price to Earnings (P/E)
- ―
- Beta
- N/A
- Next Earnings
- Mar 10, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth
The sharp 2025 revenue increase indicates meaningful commercial expansion and improving market traction. If the growth is sustained, it can provide greater operating scale, support investment in development and market access, and strengthen the company’s ability to build a broader biologics business.
Improved Leverage
The substantial reduction in debt-to-equity improves financial flexibility relative with prior years and lowers balance-sheet pressure. Increased equity and total assets also provide a stronger capital base, giving Tanvex more room to pursue development and commercialization while managing its funding needs.
Biosimilar Business Focus
A focused biosimilar strategy addresses established biologic therapies while targeting affordability, creating a structurally relevant commercial opportunity. Tanvex’s combination of research, clinical development, manufacturing preparation, and market access activities supports an integrated pathway from product development toward commercialization.
Bears Say
Persistent Operating Losses
Persistent operating and net losses show that the business has not yet reached earnings stability despite strong revenue growth. Continued losses can constrain reinvestment, weaken shareholder returns, and make future performance dependent on achieving much better operating leverage and cost control.
Negative Cash Generation
Sustained negative operating and free cash flow means current activities consume rather than generate capital. This limits financial resilience and reduces the funds available for clinical development, manufacturing preparation, and commercialization, leaving improvement in cash conversion as a major requirement for durable growth.
Continued Funding Dependence
Even with improved leverage, ongoing operating deficits leave Tanvex reliant on external funding until performance improves. That dependence can restrict strategic flexibility, increase execution pressure, and make the company more vulnerable to financing requirements while it advances its biologic and biosimilar pipeline.
TANVF FAQ
What is Tanvex Biopharma’s market cap?
When is Tanvex Biopharma’s upcoming earnings report date?
How were Tanvex Biopharma’s earnings last quarter?
Is Tanvex Biopharma overvalued?
Does Tanvex Biopharma pay dividends?
What is Tanvex Biopharma’s EPS estimate?
How many shares outstanding does Tanvex Biopharma have?
What happened to Tanvex Biopharma’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Tanvex Biopharma?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Tanvex Biopharma
Tanvex BioPharma, Inc., originally known as Ruenvex Biotech, Inc., is a biopharmaceutical company founded in 2013 and based in George Town, Cayman Islands. The firm specializes in the investigation, creation, production, and sale of biosimilar medicines, with its operations spanning Taiwan and the United States. Its core mission involves developing biosimilars aimed at treating severe conditions like neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. The company's robust product portfolio includes TX01 and TX-05, both of which have successfully completed Phase III clinical trials. Additionally, TX-04 and TX-16 are currently undergoing Phase I clinical trials, while TX-52 and other potential therapies are in the pre-clinical development stage.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Stephen Lam
- Employees
- 215
- Website
- www.tanvex.com
- Address
- 802 West Bay Road, George Town, TP, KY1-1205, KY

